Ignite Creation Date:
2025-12-25 @ 4:33 AM
Ignite Modification Date:
2025-12-26 @ 3:35 AM
Study NCT ID:
NCT06564818
Status:
RECRUITING
Last Update Posted:
2025-12-23
First Post:
2024-08-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003865', 'term': 'Depressive Disorder, Major'}, {'id': 'D003863', 'term': 'Depression'}], 'ancestors': [{'id': 'D003866', 'term': 'Depressive Disorder'}, {'id': 'D019964', 'term': 'Mood Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D001526', 'term': 'Behavioral Symptoms'}, {'id': 'D001519', 'term': 'Behavior'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 220}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-12-17', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2026-09', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-22', 'studyFirstSubmitDate': '2024-08-20', 'studyFirstSubmitQcDate': '2024-08-20', 'lastUpdatePostDateStruct': {'date': '2025-12-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2024-08-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-08', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Montgomery-Åsberg Depression Rating Scale (MADRS)', 'timeFrame': 'Screening Day-45, Baseline Day-1, Day 2, Day 10, Day 21, Day 23, Day 31, and Day 42 (End of Treatment)', 'description': 'The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phrased questions about symptoms to more detailed ones allowing a precise rating of severity.'}], 'secondaryOutcomes': [{'measure': 'The Beck Depression Inventory-Second Edition (BDI-II)', 'timeFrame': 'Baseline Day-1, Day 21, and Day 42 (End of Treatment)', 'description': 'The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity.'}, {'measure': 'The Clinical Global Impression Scale (CGI-S)', 'timeFrame': 'Screening Day-45, Baseline Day-1, and Day 42 (End of Treatment)', 'description': 'The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement, and efficacy index. Only the severity of illness and global improvement measures will be utilized for this trial.'}, {'measure': 'The Generalized Anxiety Disorder 7-item scale (GAD-7)', 'timeFrame': 'Baseline Day-1, Day 21, and Day 42 (End of Treatment)', 'description': 'The Generalized Anxiety Disorder 7-item scale (GAD-7) is a 7-item self-reported assessment that measures the severity of generalized anxiety disorder symptoms.'}, {'measure': 'The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)', 'timeFrame': 'Baseline Day-1, Day 21, and Day 42 (End of Treatment)', 'description': 'The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self-reported measure used to evaluate intervention-related changes in quality of life, divided into the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Major Depressive Disorder', 'MDD', 'Psilocybin', 'Psychedelic', 'Psilocin', 'CYB003', 'CYB003-001', 'Depression'], 'conditions': ['Major Depressive Disorder']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.approach-mdd-trial.com/', 'label': 'Apply for Trial Here'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '85 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\nParticipants must meet all the following criteria to be included in the trial:\n\n* Aged 18 to 85 years inclusive, at Screening\n* Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR \\[if single episode, duration of ≥4 weeks and ≤24 months\\] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.\n* Depression is of moderate to severe degree at Screening, independently confirmed by additional clinical assessments\n* Participant has been on a stable dose of a single antidepressant medication at an adequate dose (label specified) for an adequate duration in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator and clinical interviews.\n* Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤ 40 kg/m2), inclusive, at Screening.\n* Participant is able to refrain from nicotine use during the dosing session (up to 8 hours)\n* Registered with a healthcare professional who can confirm the diagnosis and previous treatments received by the participant.\n* Participants capable of producing sperm must use a condom during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential. In addition, their partner of childbearing potential must use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) from first dosing until 12 weeks following final dosing.\n* Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day -1 prior to dosing.\n* Female participants who were capable of producing eggs (ova) must be postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. Postmenopausal is defined as spontaneous amenorrhea for at least 12 months, and a serum follicle-stimulating hormone level in the menopausal range, unless the participant is taking hormone replacement therapy or is using hormonal contraception.\n* Participant has provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.\n\nExclusion Criteria:\n\nParticipants with any of the following characteristics/conditions will be excluded from trial participation:\n\n* Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, attention deficit hyperactivity disorder, current or previous history of bipolar disorder, or current borderline personality disorder.\n* Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first degree relatives).\n* Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.\n* Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose for an adequate duration as judged by the Investigator and clinical interview.\n* Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.\n* Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressant, mirtazapine, trazodone, moclobemide, buspirone, ketamine or S-ketamine, or an antipsychotic or mood stabilizer for MDD.\n* Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 4 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.\n* Clinically relevant history of abnormal physical health interfering with the trial as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal \\[including dyspepsia or gastroesophageal reflux disease\\], hepatic, or renal disorder).\n* Participants with renal insufficiency.\n* Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication with no change in dosage for at least 12 weeks prior to Screening.\n* Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate or blood pressure\n* History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism, or excretion of the trial medication.\n* Participant has a presence or relevant history of organic brain disorders (e.g., epilepsy, seizure, intracranial hypertension, intracranial bleed and aneurysmal disease, brain tumor or other medical conditions associated with seizures or convulsions).\n* Known sensitivity to psilocin and/or any excipients present in the formulation.\n* Participant is taking or has taken OTC doses of 5 hydroxytryptophan or St John's Wort within 45 days prior to trial medication administration.\n* Strenuous exercise within 48 hours prior to each clinic visit.\n* The participant has participated in a clinical trial and has received a medication or a new chemical entity within 12 weeks prior to dosing of current trial medication.\n* Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.\n* Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.\n* History of serotonin syndrome.\n* Unwilling to consent to audio and video recording of psychological support and dosing sessions."}, 'identificationModule': {'nctId': 'NCT06564818', 'acronym': 'APPROACH', 'briefTitle': '"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"', 'organization': {'class': 'INDUSTRY', 'fullName': 'Cybin IRL Limited'}, 'officialTitle': 'A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder', 'orgStudyIdInfo': {'id': 'CYB003-002'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Experimental Arm A: CYB003 in 2 of 2 Dosing Sessions', 'description': 'Arm A participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study.', 'interventionNames': ['Drug: CYB003', 'Behavioral: Psychological Support']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo Comparator Arm B: Placebo in 2 of 2 Dosing Sessions', 'description': 'Arm B participants will receive placebo in 2 of 2 Dosing Sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial.', 'interventionNames': ['Behavioral: Psychological Support', 'Drug: Placebo']}], 'interventions': [{'name': 'CYB003', 'type': 'DRUG', 'description': 'CYB003 is a Deuterated Psilocin Analog.', 'armGroupLabels': ['Experimental Arm A: CYB003 in 2 of 2 Dosing Sessions']}, {'name': 'Psychological Support', 'type': 'BEHAVIORAL', 'description': 'Manualized psychological support performed by facilitators', 'armGroupLabels': ['Experimental Arm A: CYB003 in 2 of 2 Dosing Sessions', 'Placebo Comparator Arm B: Placebo in 2 of 2 Dosing Sessions']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo', 'armGroupLabels': ['Placebo Comparator Arm B: Placebo in 2 of 2 Dosing Sessions']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85022', 'city': 'Phoenix', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Sue Sisley', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Scottsdale Research Institute', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '85050', 'city': 'Phoenix', 'state': 'Arizona', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Ruchir Gupta', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Mountain Clinical Trials', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '85704', 'city': 'Tucson', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Stephen Adams', 'role': 'CONTACT', 'email': 'sa@nobleclinicalresearch.com', 'phone': '520-612-7560'}, {'name': 'Brandon Yates', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Noble Clinical Research', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '85715', 'city': 'Tucson', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Steven Bupp', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Del Sol Research Management', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '90706', 'city': 'Bellflower', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '949-350-0492'}, {'name': 'Robert Bota', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CenExel CIT (Clinical Innovations, Inc)', 'geoPoint': {'lat': 33.88168, 'lon': -118.11701}}, {'zip': '92037', 'city': 'La Jolla', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'email': 'bellar@kadimanp.com'}, {'name': 'David Feifel', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Kadima Neuropsychiatry Institute', 'geoPoint': {'lat': 32.84727, 'lon': -117.2742}}, {'zip': '90025', 'city': 'Los Angeles', 'state': 'California', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Nima Fahimian', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Bespoke Treatment/Lipov Medical Group', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '91763', 'city': 'Montclair', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Stephen Volk', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Catalina Research Institute', 'geoPoint': {'lat': 34.07751, 'lon': -117.68978}}, {'zip': '92056', 'city': 'Oceanside', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Sherry Soefje', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Excell Research, Inc', 'geoPoint': {'lat': 33.19587, 'lon': -117.37948}}, {'zip': '94114', 'city': 'San Francisco', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '415-669-6287'}, {'name': 'Sidney Edsall', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Open Mind Collective/UCSF Medical Center Mount Zion', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '92675', 'city': 'San Juan Capistrano', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '909-488-9116'}, {'name': 'Neelima Kunam', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Inland Psychiatric Medical Group Inc', 'geoPoint': {'lat': 33.50169, 'lon': -117.66255}}, {'zip': '80209', 'city': 'Denver', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '720-941-9363'}, {'name': 'Sara Markey', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Mountain View Clinical Research', 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'zip': '80439', 'city': 'Evergreen', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Dana Lerman', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Starlight Clinical Research', 'geoPoint': {'lat': 39.63332, 'lon': -105.31721}}, {'zip': '33024', 'city': 'Hollywood', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '954-990-7649'}, {'name': 'Edwin Gomez', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Research Centers of America', 'geoPoint': {'lat': 26.0112, 'lon': -80.14949}}, {'zip': '32751', 'city': 'Maitland', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '407-676-5252'}, {'name': 'Sejal Patel', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'K2 Medical Research-Maitland', 'geoPoint': {'lat': 28.62778, 'lon': -81.36312}}, {'zip': '33135', 'city': 'Miami', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '786-238-7099'}, {'name': 'Emilio Mantero', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Floridian Neuroscience Institute', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33161', 'city': 'North Miami', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Danielle Recasens', 'role': 'CONTACT', 'email': 'drecasens@segaltrials.com'}, {'name': 'Rishi Kakar, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Innovative Clinical Research, INC', 'geoPoint': {'lat': 25.89009, 'lon': -80.18671}}, {'zip': '32801', 'city': 'Orlando', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Julia Salmon', 'role': 'CONTACT', 'email': 'jsalmon@cnshealthcare.com', 'phone': '407-425-5100'}, {'name': 'Robert Molpus', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Clinical Neuroscience Solutions, Inc', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '32803', 'city': 'Orlando', 'state': 'Florida', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jorel Martinez', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Charter Research', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '32807', 'city': 'Orlando', 'state': 'Florida', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Eric Carbonell', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Combined Research Orlando Phase I-IV', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '32751', 'city': 'Tampa', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '813-500-5252'}, {'name': 'Kelly Yokum', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'K2 Medical Research-Tampa', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '30331', 'city': 'Atlanta', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Amber Tannahill', 'role': 'CONTACT', 'email': 'a.tannahill@cenexel.com', 'phone': '404-881-5800'}, {'name': 'Elyssa Barron, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Atlanta Center for Medical Research, CenExel', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '30330', 'city': 'Decatur', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Morgan Hecker', 'role': 'CONTACT', 'email': 'm.hecker@cenexel.com', 'phone': '404-537-1281'}, {'name': 'Katherine Prowse', 'role': 'CONTACT', 'email': 'k.prowse@cenexel.com', 'phone': '404-537-1281'}, {'name': 'Kimball Johnson, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CenExel iResearch Atlanta', 'geoPoint': {'lat': 33.77483, 'lon': -84.29631}}, {'zip': '31405', 'city': 'Savannah', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '912-744-0800'}, {'name': 'Nancy Backus', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'CenExel iResearch Savannah', 'geoPoint': {'lat': 32.08354, 'lon': -81.09983}}, {'zip': '60640', 'city': 'Chicago', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jeff Ross', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Great Lakes Clinical Trials, DBA Flourish Research', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60640', 'city': 'Chicago', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jennifer Rhode', 'role': 'CONTACT', 'email': 'jrohde@uptownresearch.com', 'phone': '773-989-8313'}, {'name': 'John Sonnenberg', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Uptown Research Institute', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60076', 'city': 'Skokie', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'John Zajecka', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Psychiatric Medicine Associates, LLC', 'geoPoint': {'lat': 42.03336, 'lon': -87.73339}}, {'zip': '70115', 'city': 'New Orleans', 'state': 'Louisiana', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Caroline Campion', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'DelRicht Research', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '20850', 'city': 'Rockville', 'state': 'Maryland', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '301-750-3401'}, {'name': 'Manish Agrawal', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Sunstone Medical, PC', 'geoPoint': {'lat': 39.084, 'lon': -77.15276}}, {'zip': '02116', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Darin Dougherty', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Adams Clinical Boston', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '02472', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '617-744-8542'}, {'name': 'Daniel Rutrick', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Adams Clinical', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '01103', 'city': 'Springfield', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Adnan Dahdul', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Elixia Health', 'geoPoint': {'lat': 42.10148, 'lon': -72.58981}}, {'zip': '89119', 'city': 'Las Vegas', 'state': 'Nevada', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jelena Kunovac', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Redbird Research, LLC', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '89121', 'city': 'Las Vegas', 'state': 'Nevada', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Zinoviy Benzar', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Oasis Clinical Trials', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '08540', 'city': 'Princeton', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Sanjay Varma', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Global Medical Institues, Princeton Medical Institute', 'geoPoint': {'lat': 40.34872, 'lon': -74.65905}}, {'zip': '100029', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Rachel Noone', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Adams Clinical Harlem', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10461', 'city': 'The Bronx', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Shama Farooq', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Adams Clinical Bronx', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '28112', 'city': 'Monroe', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Rasheed Onafuye', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Monroe Biomedical Research', 'geoPoint': {'lat': 34.98543, 'lon': -80.54951}}, {'zip': '44720', 'city': 'North Canton', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '330-493-1118'}, {'name': 'Shishuka Malhotra', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Neurobehavioral Clinical Research', 'geoPoint': {'lat': 40.87589, 'lon': -81.40234}}, {'zip': '38119', 'city': 'Memphis', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '901-843-1045'}, {'name': 'Valerie Arnold', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Clinical Neuroscience Solutions, CNS Healthcare', 'geoPoint': {'lat': 35.14953, 'lon': -90.04898}}, {'zip': '75115', 'city': 'DeSota', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '972-283-6286'}, {'name': 'Rajinder Shiwach', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'InSite Clinical Research, LLC'}, {'zip': '77433', 'city': 'Houston', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Flavia Thomas', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Zillan Clinical Research', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '75093', 'city': 'Plano', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '469-364-8804'}, {'name': 'Sejal Mehta', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'AIM Trials', 'geoPoint': {'lat': 33.01984, 'lon': -96.69889}}, {'zip': '84107', 'city': 'Murray', 'state': 'Utah', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Tiana Tangulu', 'role': 'CONTACT', 'email': 'tiana.tangulu@numinus.com', 'phone': '801-369-4219'}, {'name': 'Tera Wolf', 'role': 'CONTACT', 'email': 'tera.wolf@numinus.com', 'phone': '801-369-4219'}, {'name': 'Paul Thielking', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Cedar Clinical Research', 'geoPoint': {'lat': 40.66689, 'lon': -111.88799}}, {'zip': '84058', 'city': 'Orem', 'state': 'Utah', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Reid Robison', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Inner Space Research, LLC', 'geoPoint': {'lat': 40.2969, 'lon': -111.69465}}], 'centralContacts': [{'name': 'Clinical Development', 'role': 'CONTACT', 'email': 'clinicaltrialsinfo@cybin.com', 'phone': '877-361-4003'}], 'overallOfficials': [{'name': 'Clinical Development', 'role': 'STUDY_CHAIR', 'affiliation': 'Cybin IRL Limited'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Cybin IRL Limited', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}